{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=43&state=California", "query": { "state": "California", "city": "Fullerton", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1113, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=44&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=42&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T07:09:51.188Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00571649", "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Rivaroxaban placebo", "type": "DRUG" }, { "name": "Enoxaparin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 8101, "start_date": "2007-12", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571649" }, { "nct_id": "NCT03931785", "title": "A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Irritable Bowel Syndrome With Diarrhea (IBS-D)" ], "interventions": [ { "name": "MD-7246", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ironwood Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2019-05-01", "completion_date": "2020-03-11", "has_results": true, "last_update_posted_date": "2021-03-12", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 80, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 65 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03931785" }, { "nct_id": "NCT00938652", "title": "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine/carboplatin", "type": "DRUG" }, { "name": "Iniparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 519, "start_date": "2009-07", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-09-19", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 102, "location_summary": "Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00938652" }, { "nct_id": "NCT02844816", "title": "Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Bladder Urothelial Carcinoma", "Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage I Bladder Urothelial Carcinoma AJCC v6 and v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2017-03-13", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 269, "location_summary": "Daphne, Alabama • Mobile, Alabama • Scottsdale, Arizona + 201 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02844816" }, { "nct_id": "NCT05310071", "title": "A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Aducanumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "60 Years to 85 Years" }, "enrollment_count": 1027, "start_date": "2022-06-02", "completion_date": "2024-08-12", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 130, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05310071" }, { "nct_id": "NCT00219284", "title": "Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease With End of Dose Wearing Off" ], "interventions": [ { "name": "Carbidopa/levodopa/entacapone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 359, "start_date": "2005-01", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2017-03-30", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Fullerton, California • Irvine, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00219284" }, { "nct_id": "NCT00575055", "title": "Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Bapineuzumab 0.5 mg/kg", "type": "DRUG" }, { "name": "Placebo Control", "type": "DRUG" }, { "name": "Bapineuzumab 1.0 m/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "JANSSEN Alzheimer Immunotherapy Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "88 Years", "sex": "ALL", "summary": "50 Years to 88 Years" }, "enrollment_count": 1121, "start_date": "2007-12", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00575055" }, { "nct_id": "NCT06521385", "title": "Comparison of Non-invasive Respiratory Monitoring System (RMS) to Capnography for Respiratory Rate (RR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Respiratory Monitoring" ], "interventions": [ { "name": "Makani Science Respiratory Monitoring System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Makani Science", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "22 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "22 Years to 99 Years" }, "enrollment_count": 32, "start_date": "2024-05-17", "completion_date": "2024-07-02", "has_results": true, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06521385" }, { "nct_id": "NCT00151749", "title": "WelChol® and Insulin in Treating Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Colesevelam hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 260, "start_date": "2004-06", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2012-01-18", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 45, "location_summary": "Tuscumbia, Alabama • Sierra Vista, Arizona • Jonesboro, Arkansas + 42 more", "locations": [ { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Sierra Vista", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00151749" }, { "nct_id": "NCT01647828", "title": "A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "OMP-59R5", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 217, "start_date": "2012-10", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2023-02-15", "last_synced_at": "2026-11-05T07:09:51.188Z", "location_count": 26, "location_summary": "Goodyear, Arizona • Bakersfield, California • Fullerton, California + 23 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01647828" } ] }